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Abstract: Background and Objectives: There is a paucity of integrated knowledge regarding legal
considerations required to ensure patient safety through safe medicines management. This study ex-
plores the legal considerations surrounding medicines management, providing a synthesis of existing
knowledge. An integrative systematic review of the current international knowledge was performed.
Materials and Methods: The search encompassed the online databases of PubMed (including Medline),
Scopus, CINAHL, and Web of Science using MeSH terms and relevant keywords relating to the legal
considerations of medicines management in healthcare settings. Results: The search process led to
the identification of 6051 studies published between 2010 and 2020, of which six articles were found
to be appropriate for data analysis and synthesis based on inclusion criteria. Research methods
were varied and included qualitative interviews, mixed-methods designs, retrospective case reports
and cross-sectional interrupted time-series analysis. Their foci were on the delegation of medicines
management, pharmacovigilance and reporting of adverse drug reactions (ADRs) before and after
legislation by nurses, physicians and pharmacists, medico-legal litigation, use of forced medication
and the prescription monitoring program. Given the heterogenicity of the studies in terms of aims
and research methods, a meta-analysis could not be performed and, therefore, our review findings
are presented narratively under the categories of ‘healthcare providers’ education and monitoring
tasks’, ‘individual and shared responsibility’, and ‘patients’ rights’. Conclusion: This review identifies
legal aspects surrounding medicines management, including supervision and monitoring of the
effects of medicines; healthcare providers’ knowledge and attitudes; support and standardised tools
for monitoring and reporting medicines’ adverse side effects/ADRs; electronic health record systems;
individual and shared perceptions of responsibility; recognition of nurses’ roles; detection of sentinel
medication errors; covert or non-voluntary administration of medication, and patient participation.
Keywords: clinical practice; law; legal; adverse drug reactions; pharmacovigilance; medicines
management; patient safety
1. Introduction
Health care is a complex system in which patients often experience harm resulting from
the healthcare process itself [1,2]. It is too frequently accompanied by adverse events and
medical errors [3], which are often preventable [4]. The World Health Organization (WHO)
indicates that harm is caused in approximately one in 10 hospitalized patients, with at least
50% of these harms being preventable. Estimates show that 421 million hospitalizations
take place worldwide every year and that during hospitalization about 42.7 million adverse
events occur, and 18.3% of adverse events are attributed to medication errors [5]. A
systematic review of 25 studies conducted in 27 countries showed that 2.9–21.9% of patients
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were affected by at least one adverse event, many of which were medication-related, and
34.3–83% could be prevented [6]. Beside deaths and serious adverse drug reactions (ADRs)
in community settings, 128,000 patient deaths from prescribed medicines are reported
annually in hospitals in the USA [7]. Therefore, measures for improving the quality of
healthcare ensure or optimise patient safety “as the absence of preventable harm to a patient
during the process of health care and reduction of risk of unnecessary harm associated with
health care to an acceptable minimum” [8]. These efforts have gained critical international
significance: in 2004, the founding of the World Alliance for Patient Safety by the WHO
provided an initiative to focus on and improve the quality of care and patient safety. This
alliance cooperates with health-related partners, e.g., with the 24 participating ministries of
health or National Patient Safety Agencies, to achieve global improvement in healthcare,
including the prescribing, dispensing and administering of medicines [9]. The European
Commission (EC) intensified further developments to improve the safety of health care
in Europe with the Luxembourg Declaration on Patient Safety in 2005. This indicates that
50% of all preventable adverse events are a consequence of ‘medication errors’, and has
led to the development of specific recommendations to Europe-wide institutions, national
authorities and healthcare providers [10,11].
Medicines Management and Law
The overall goal of healthcare interventions is to ensure safe and high-quality patient
care [12] through the safe and effective use of medications for the treatment of diseases [13].
There is a growing demand for the prescription of medications to treat age-related and
chronic diseases worldwide. As an example, in Organisation for Economic Co-operation
and Development (OECD) countries in 2017, the retail trade in pharmaceuticals accounted
for one-fifth of all healthcare expenditures, averaging $564 per person [14]. Medicines
have the ability to prevent, treat and cure diseases, but errors in the medication process
that determines how medicines are used can cause damage. Therefore, the nature of
pharmacotherapy demands that systems be in place to ensure the correct use of medicines,
and that all transactions relating to medications be governed by appropriate laws and
regulations [10].
According to the WHO Constitution (1946), “the highest attainable standard of health
is a fundamental right of every human being”. Therefore, legal considerations are taken up
by all countries through domestic or constitutional law to ensure access to high quality and
safe health care [15]. It regulates behaviours or procedures that must be followed by indi-
viduals for maintaining human health, controlling or changing personal and professional
behaviours [3].
Medicines management, as the handling of medications and medicinal products by
healthcare professionals, consists of prescribing, dispensing, distributing, administration,
patient education, follow up and monitoring, and is regulated by law [13,16]. In most
cases, such laws contain a legal definition of a medicine, which also influences what can be
purchased over the counter and when a prescription is required to obtain a medication. This
provides a framework for governments to monitor the use of medications in the workplace,
and defines how and according to which guidelines medications can be administered,
including provisions for emergency situations [13]. Nonetheless, there are international
differences in regulations for medicines management. In the United States, the Food
and Drug Administration (FDA) of the U.S. Department of Health and Human Services
pursues the protection of public health, which includes monitoring the safety and efficacy
of medications. In many ways, the Drug Amendments of 1962 by the FDA is a model
followed by other countries [17]. Within the European Union (EU), medicines law consists
of European Commission directives and regulations that member states incorporate into
national law [10].
Principles of medicines management developed based on laws and regulations should
be unambiguously communicated through guidelines to healthcare professionals for in-
dispensable use in clinical practice [18,19]. From the prescription to the administration
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of a medicine to a patient, physicians, nurses and pharmacists collaborate as a multidis-
ciplinary team. However, problems can arise due to the unclear legal arrangements for
medicines management [18]. Costs arising from additional hospital stays, litigation costs,
hospital-acquired infections, loss of income, disability, and medical expenses have been
reported as $6 to $29 billion annually [5].
Legal considerations to ensure patient safety through safe medicines management
are therefore at the top of the political agenda, but there is a paucity of integrated knowl-
edge. Accordingly, this systematic review of the international literature aims to answer
the following question: what are the legal considerations for medicines management in
healthcare settings?
2. Materials and Methods
2.1. Design
A systematic review of literature was carried out as an explicit and objective research
method for data collection and knowledge synthesis to reach our study aim [20]. An
integrative approach to systematic reviewing was chosen, involving both qualitative and
quantitative studies. It aims at summarising empirical or theoretical literature to provide a
more comprehensive understanding of healthcare problems and can inform future research,
clinical practice, and policy initiatives [21].
2.2. Search Method and Inclusion Criteria
The research protocol was developed (Appendix A) and three authors (MV, SA, MG)
participated in the search process using four large online international databases that cover
the majority of life sciences’ citations: PubMed (including Medline), Scopus, CINAHL and
Web of Science. A reference librarian was approached to check the search process. The
search aimed to retrieve articles published in English in the decade from 2010 to 2020.
To maximise the number of studies retrieved, a pilot search in general and specialised
databases, based on our experience of medicines management, was undertaken. This
identified all MeSH terms and all relevant keywords relating to the ‘legal considerations’ for
‘medicines management’. Boolean operators (AND, OR) were used to build search phrases
and search titles and abstracts. Grey literature on policy documents, clinical guidelines and
cross-references from bibliographies were used to improve the search coverage.
Inclusion criteria were empirical studies with a focus on legal considerations of
medicines management in clinical practice, in short-term and long-term healthcare settings,
and published in online peer-reviewed scientific journals. Thus, reviews, commentaries, let-
ters, conference proceedings, and those studies with a concentration on medicines management
in places other than healthcare settings were excluded. The authors independently screened the
titles, abstracts, and full texts of the retrieved studies, held discussions, and reached agreement
regarding the inclusion of selected studies based on the inclusion criteria.
2.3. Quality Appraisal
Appropriate tools to the selected studies’ methods were used, including the Strength-
ening the Reporting of Observational Studies in Epidemiology (STROBE) (for cross-
sectional studies, maximum score 30) [22], the Critical Appraisal Skills Programme (CASP)
for qualitative studies (maximum score 10) [23], Mixed Methods Appraisal Tool (MMAT)
(maximum score 17) [24], and Joanna Briggs Institute (JBI) Critical Appraisal Checklist for
Case Reports (maximum score 8) [25]. Overall, the final decision on the importance and
methodological quality of each study for inclusion or exclusion was made after holding
discussions between the authors and reaching agreement.
2.4. Data Abstraction and Knowledge Synthesis
A pre-piloted data extraction table was developed to import data from selected studies
and categorise them according to: author’s name, publication year, country, design, sample
size and setting, and main findings concerning legal aspects of medicines management in
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healthcare settings. Before the full data extraction, the table was pilot-tested to ensure that
it suited the review aim by including the required data for knowledge analysis [20].
Variations within the selected studies in terms of aims and methods precluded a
meta-analysis. Therefore, the review findings are presented narratively based on the
Preferred Reporting Items Systematic Reviews and Meta-Analysis (PRISMA) statement [26].
Categories were developed by the authors based on differences and similarities in the
studies’ findings. The authors undertook discussions to reach agreements on assigning the
studies’ findings into the categories.
3. Results
3.1. Search Results and Study Selections
The literature search in the databases led to the retrieval of 6051 articles in total
from four databases (Figure 1). Deletion of duplicate titles and irrelevant studies based
on independent title and abstract reading by the authors led to a final selection of 42
studies. They were carefully checked through abstract-reading with an outcome of seven
studies fully meeting the inclusion criteria, which were selected for full-text reading and
appraisal (Table 1). Excluded studies discussed the social aspects influencing medication
rather than legal considerations in healthcare settings or had no exact relevance to patient-
safety principles.
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Figure 1. The process of the review adapted from the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) [26]. The PRISMA Statement distributed under the terms of
the Creative Commons Attribution License.
The full-texts were obtained from the Norwegian library and were carefully read
in order to select only those studies with a precise focus on the legal considerations of
medicines management and related factors in healthcare settings, and those with a high-
quality method in their research processes based on scores achieved using the appraisal
tools. The full-text of one article was in French and was thus excluded, leaving six studies
for full-text appraisal. The remaining articles (n = 6) were relevant to the review topic and
had acceptable research structure and framework quality (Table 2). No further studies were
found for inclusion during the grey literature and manual search in the reference lists of
the selected studies.
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Table 1. The search strategy and results of different phases of the review.





(medication OR drug OR medicines OR “pharmaceutical
preparations” OR pharmaceuticals OR “medicines
management”) AND (law OR rule OR regulation OR
principle OR legislation OR Act OR guideline OR legal OR
bill OR convention OR policy OR obligation OR “breach of
duty” OR “legal duty” OR accountability OR responsibility
OR “patient’s right” OR litigation OR duty)
PubMed (including Medline) 2953 11 0 0
Scopus 1336 11 2 3
Web of Science 1460 14 2 2
Cinahl 302 6 3 1
Manual search/backtracking
references 0 0 0 0
Total of databases 6051 42 7 6
Table 2. Characteristics of selected studies for data analysis and synthesis.
Author, Year, Country Aim Methods Sample and Setting Main Finding Conclusion Full-TextAppraisal Score









20 nurses in district
healthcare centres
Incompatibility of delegation with







9 out of 10










survey and (ii) focus
group interview
(i) 154 pharmacists in the
south of country; (ii) 7
community pharmacists
4965 and 5159 reports in 2005 and
2010 were submitted, respectively:
(i) One-quarter were familiar with
ADRs reporting; (ii) 38.3% reported
ADRs, underreporting being due to
attitude issues and lack of
knowledge of casual relationship
between ADRs and medicines
Need for education and
training 14 out of 17





and the condition of
nurses’ reporting
Cross-sectional




898 and 1074 reports to the
pharmacovigilance system in 2005
and 2010, respectively; 31% and 24%
of reports made by nurses in
these years




22 out of 30
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Table 2. Cont.
Author, Year, Country Aim Methods Sample and Setting Main Finding Conclusion Full-TextAppraisal Score









206 cases of medico-legal
litigation settled in an
urban hospital from
2014–2015
20% of the cases remained
unreported due to the latency




establishment of a model
for rapid reporting
6 out of 8
Gøtzsche et al., 2019,
Denmark [31]
To investigate if the law










No clear indication of the suitability
of treatment to the patient’s interest;
violation of the law on the use of
forced medications with the lowest
adverse effects (97%)
Abandonment of forced
medication use 6 out of 8
Strickler et al., 2019,
USA [32]




the programs’ use and
prescription-based









Legal mandates increased the
prescription and use of the
programs; reduction of the multiple









24 out of 30
ADRs: adverse drug reactions.
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3.2. General Characteristics of the Selected Studies
Table 2 provides an overview of the general characteristics of the selected studies for
data analysis and synthesis. The studies were published between 2013 and 2019 and were
conducted in Sweden [27,29], Portugal [28], Italy [30], Denmark [31] and USA [32].
There were variations in the studies’ methods and research foci. One study comprised
qualitative interviews focusing on nurses’ perspectives of delegation of medicines manage-
ment to unlicensed/ unregistered staff [27]; another was a mixed-methods study consisting
of survey and focus groups with pharmacists regarding ADR reporting and knowledge of
pharmacovigilance legislation [28]; two studies were retrospective case reports of medico-
legal litigation and the management of clinical risk [30] and legal aspects of patients’ rights
in forced medication orders [31]; one was a cross-sectional study of ADR reporting before
and after legislation changes and the conditions for nurse reporting [29] and another was a
cross-sectional interrupted time-series analysis of prescription drug-monitoring programs
and the related patient risk [32].
3.3. Legal Considerations of Medicines Management
The review findings were classified and grouped, based on the similarities and differ-
ences between the findings of the selected studies. The classification highlighted the legal
considerations affecting medicines management in healthcare settings within the following
categories developed by the authors: ‘healthcare providers’ education and monitoring
tasks’, ‘individual and shared responsibility’ and ‘patients’ rights’. They highlighted the
interconnections of the legislation concerning medicines management, intended to improve
the quality and safety of the medication process (Figure 2).
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i legal considerations sur ounding medicines management.
Given these heterogeneities in the studies’ methods, objectives and results, we pre-
sented the results of this review narratively under categories developed based on similari-
ties and differences between the studies’ findings. A summary of the studies’ results has
been presented in Table 3.
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Responsibility Patients’ RightsAuthor, Year






Difficulty in following up
regulations; recognition of the
nurse’s role
No data
Duarte et al., 2015 [28]
Being informed and educated
about pharmacovigilance;
attitudes towards reporting










Recognition of the nurse’s role No data




Gøtzsche et al., 2019 [31] No data No data
Patient participation, decision
making for prescription and
administration
Strickler et al., 2019 [32]
The use of the electronic
health record system;
customising the law
No data No data
ADRs: adverse drug reactions.
3.3.1. Healthcare Providers’ Education and Monitoring Tasks
A series of measures to support the lawful practice of medicines management includ-
ing the education of healthcare staff and the application of monitoring tools was needed to
guarantee the implementation of regulations and rules determined by legislation, with the
aim of ensuring safe medicines management.
The education and empowerment of healthcare professionals was emphasised, based
on findings that healthcare staff frequently lacked knowledge and skills regarding medicines
management and its legal aspects.
Craftman et al., concluded delegation of medicines management to unlicensed health-
care staff could be lawful following sufficient education and training to prevent medication
errors. Also, nurses who gained their knowledge of medicines management through
practical and on-the-job training, rather than formal education, were identified as needing
education and supervision to prevent errors during the preparation of medicines, mixing
medicines, and crushing tablets before administration [27].
Duarte et al. indicated that not all pharmacists (70%) knew about the new pharma-
covigilance legislation supporting the reporting of ADRs and side effects. Some lacked
sufficient knowledge on the new definition of ADRs or lacked positive attitudes towards
checking details on the relevant websites to be able to report suspected ADRs. Therefore,
knowledge development in pharmacovigilance, clinical pharmacology and attribution of
causality for medicines’ side effects and ADRs seemed necessary [28].
Legally enforced and standardised monitoring tools would ensure reporting medicines’
side effects and ADRs.
Karlsen et al., stated that before the passing of legislation supporting ADRs reporting
in 2005, only 100 reports were submitted (ever), compared with 172 reports after legislation
came into effect in 2010, and its implementation was monitored and supported [29].
According to Strickler et al., legal sanctions that addressed over-prescription and risky
opioid use, together with the implementation of monitoring programs for the prescription
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of medicines, encouraged prescribers to actively follow medicines management guidelines
and ensure the safety of medication through efforts to customize the law and suit it to
cultural contexts that improved its effectiveness. The review and registration of the patient’s
prescription history as a monitoring tool before prescribing opioids was mandated. This
reduced multiple prescribing, the opioid prescribing rate, overlapping opioid prescriptions,
and overlapping opioid/benzodiazepine prescriptions [32].
From the perspective of Craftman et al., standardised methods for the delegation of
medicines management consisting of validated tools and guidelines were key to assess
healthcare staff’s readiness for assuming responsibility for medication and risk manage-
ment under the supervision of a licensed nurse [27]. Also, Strickler et al., believed that the
use of the electronic health record system and customising the law to suit the care context
in terms of staffing pattern and equipment helped with monitoring the medication process
and reducing the risk of medication errors, and guaranteed the implementation of legal
initiatives of medicines management [32].
3.3.2. Individual and Shared Responsibility
The success of legal initiatives supporting medicines management depended on the
creation of a sense of both individual and shared responsibility for the accurate imple-
mentation of the law. Legislation and enforcement actions could not guarantee adherence
to medicines management guidelines. Legal initiatives alone were insufficient: shared
motivation and responsibility were needed.
Craftman et al. reported that difficulties in following rules and regulations for del-
egating medication duties to unlicensed healthcare staff, combined with incompatibility
between the regulations and current practice, detracted from individual responsibility. In
general, regulations and guidelines were outdated and did not consider staff shortages,
heavy workloads and transitional care from healthcare settings to patients’ own homes,
causing a disconnect with current practice and changes [27]. In Duarte et al., whilst 66% of
pharmacists were willing to report ADRs, difficulties related to the process of reporting, in-
cluding malfunctioning websites and complicated and long reporting forms, were barriers
to individual responsibility for reporting [28].
Duarte et al. defined shared responsibility for medicines management in terms of
reporting and publishing reports of medicines’ side effects and ADRs by the entire chain of
stakeholders, from the pharmaceutical industry to healthcare settings. Legislation should
recognise the role of each healthcare worker and describe how each role is responsible
for safe medicines management [28]. Craftman et al. also stated that the duty of the
delegation of medication by nurses to other healthcare staff should be legally recognised
and supported in order to prevent interference in other healthcare staff’s responsibilities
and damaging their feeling of accountability for medicines management in community
settings [27]. Karlsen et al., found that after the introduction of legislation on reporting
ADRs in 2010, physicians more often reported (75%) than nurses (24%). Reporting of
serious ADRs stood at 3–7% and 48–49% by nurses and physicians, respectively. These
reports were mostly related to systemic antibiotics, vaccines and antivirals, nervous system
drugs, contrast media, and respiratory medications. The reduction in the number of ADR
reports by nurses after legislation introduction was attributed to inappropriate definition of
nurses’ roles in ADR reporting and restriction of their scope of practice in reporting ADRs
to a narrow subset of medications. The close contact between nurses and patients and their
general responsibility for medicines administration and assessment of their outcomes in
hospitalised patients highlighted nurses’ valuable role in improving pharmacovigilance,
but this role was not clearly specified in law and so failed to support nurses as ADR
reporters [29].
3.3.3. Patients’ Rights
Medication practice with appropriate legal oversight supported patients’ rights through:
selection of the most effective medicines with the lowest risks of adverse side effects, patient
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participation as the provision of choice between medications and information on probable
side effects and adverse reactions.
Bolcato et al. stated that sentinel cases of medication errors are unanticipated events,
unrelated to the patient’s underlying health condition, resulting in death or serious physical
or psychological damage. Sentinel medication errors during a 2-year period arising in the
course of medicines management had legal consequences, including compensation. Events
included: botulinum injection during surgery for mild equinism on the wrong foot; no
prescription of low molecular weight heparin after cardiac surgery followed by massive
pulmonary embolism; and frequent intra-detrusoral infiltration of botulinum for recurrent
cystitis, followed by bladder dysfunction and sexual impairment, of which eight cases
were compensated and 15 cases were under treatment [30].
Gøtzsche et al. highlighted the issues of ignoring the law and patients’ rights dur-
ing the medication process: 30 consecutive appeals over the forced use of mental health
medicines were reported. They included: failure to assess patients’ medical files, absence
of expert consultation regarding the necessity of prescriptions, selection of medicines with
the highest risks of adverse effects (olanzapine, risperidone, zuclopenthixol, paliperidone,
quetiapine, aripiprazole), injection, rather than oral administration, exceeding the manu-
facturers’ recommended doses, failure to attempt patient participation and motivate the
patient to accept treatment voluntarily before forced use, and lack of documentation for
forced prescriptions and the patient’s inability to give informed consent [31].
4. Discussion
This systematic review, through integrating the findings of empirical qualitative
and quantitative studies, augments our knowledge regarding the legal considerations for
medicines management in healthcare settings.
Measures to guarantee the implementation of legal initiatives and regulations for safe
medicines management depended on the education of healthcare staff and monitoring
the implementation of safety regulations. Unmet educational needs in pharmacology
and medicines management, as well as ineffective evaluation of medication practice,
represent common issues affecting patient safety across healthcare disciplines [33]. Knowl-
edge of the law and legal considerations surrounding medicines management is often
under-represented in healthcare curricula [34]. However, the development of medicines
management competencies requires appropriate clinical education and supervision [35,36]
and should encompass the appropriate use of standard checklists and the development of
action plans to remove the gap between policymaking and implementation in practice [37].
Standardised safe medication checklists as monitoring tools have been proven to be effec-
tive in preventing lapses and reducing the incidence of adverse events by ensuring the
implementation of the law and adherence to related guidelines [38].
This review highlighted the need for standardised tools to guide the implementation
of legal initiatives and facilitate the participation of healthcare providers and patients in
medicines management. Structures and processes that standardise care are key to pre-
venting medication errors [39]. Surveillance systems should encompass all aspects of
the medication cycle, including prescribing, distribution, administration and monitor-
ing [40]. Systematized, formal and documented processes help to identify and address
medication errors and adverse events while they are still containable, and before harm occurs
to patients [19,41]. Risk assessment tools and corresponding standards, and/or national
guidelines for monitoring and handling certain high-risk medications increase the safety
of administration, and similar process should be applied to encourage reporting of er-
rors [42,43].
Our review indicates that reporting of ADRs is suboptimal and would be improved
by a more robust legal framework. An ADR is an unintended and harmful reaction in
the patient to a medicine associated with any administered dose, which can lead to life-
threatening conditions, persistent disability, hospitalization, and even a patient’s death [44,45].
Under-reporting of ADRs has been attributed to limited knowledge among healthcare
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providers and limited durability of related educational interventions [46]. Additionally,
poor awareness of the risks of under-reporting, particularly underestimation of these risks,
inappropriate reporting tools, delayed or no feedback on reported ADRs, and fear of legal
liability have been mentioned as common barriers to reporting ADRs [47]. Most reporting
systems and electronic medical records contain no specific category for ADRs [48]. Training
activities to rationally prescribe, distribute, and monitor medications with close follow-
up for adverse reactions, and reporting mechanisms, are the main steps to improving
pharmacovigilance [49–51]. Although national error reporting systems exist in many
countries, the number of ADRs reported remains low and the quality of reports is often
poor [19,48]. An intervention programme using the incorporation of legal aspects of
medicines management and education via posters, lectures and electronic distance learning
can enhance the knowledge and attitudes of caregivers towards reporting [19,52,53].
According to the review findings, the prescription and administration of medications
should be directly addressed by the law. The presence of the law unifies the area of
accountability among healthcare providers, allowing patients to benefit from medicines’
therapeutic effects as well as protecting them against medications’ harmful effects [53].
Clear laws and regulations for medicines management are the required underpinnings
for clinical practice guidelines, which support safe and effective handling of medicines
by healthcare providers [54]. Medication errors happen often when healthcare providers
have insufficient knowledge about rules, modify rules or do not follow them in full [55].
Therefore, regular education to update knowledge and understanding of the medico-
legal aspects of patient care is required to ensure quality of care [56]. All healthcare
professionals have a duty to follow rules and regulations for safe medication practice.
If these cannot be followed because of systemic deficiencies, professionals are obliged
to report system shortcomings and suggest remedies [57]. It is thus the responsibility
of healthcare managers to ensure that safety systems are in place and to ensure patient
safety through the consideration of legal, regulatory, ethical, humanistic and practical
considerations in addressing medication adverse events [58].
Incorporating medicines management programs into the electronic health record
system was found to be important. Structured medication interventions using computer-
ized decision support systems improves the appropriateness and accuracy of medication
regimens among hospitalized patients [59]. In spite of current shortcomings in updated
protocols for new medications, the use of electronic systems for medication prescription
may improve patient safety through enhancing interprofessional communication and ac-
countability [60]. For example, the use of digital devices that remind patients to take a pill,
verify the actual intake, and collect and send related data to a remote computer system
have been helpful. However, this raises questions about patients’ rights to autonomy and
potentially violates privacy rights through the secondary use of patient data and healthcare
providers’ data, which has implications for liability [61,62].
According to this review, individual and shared responsibility were required for the
successful implementation of legal initiatives supporting medicines management. How-
ever, barriers to shared responsibilities included: the lack of knowledge of ADRs and
reporting systems, incompatibility between the law and the healthcare context, and lack
of recognition of healthcare staff roles in medicines management. While there is no con-
sensus about which healthcare profession is most suited to medicines management roles,
it is accepted that trained and competent staff should assume these critical roles [63,64].
Shared decision making as a means of acknowledging power differentials and providing
information about medicines should be routine in all areas of health care, but this aspect
of medicines management is under-represented in existing literature [65]. Since medica-
tion errors involve different healthcare professionals, a collaborative approach, especially
among vulnerable patients, has been suggested [66]. Collaboration through communica-
tion, sharing information and the provision of regular feedback can improve adherence
to the principles of safe medication practice [39]. Nurses have the required knowledge
and skills regarding medicines management and spend more time with patients than
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physicians and pharmacists, increasing their chances of detecting medicines discrepancies
and near misses [67–69]. Therefore, nurses’ role, accountability and knowledge of medi-
cations should be taken into account when strategies are devised to improve medicines
management [19,66,70].
In our review the law should support how to detect near misses and medication
errors with a sentinel identity, help prevent patient harm and reduce its impact on patients.
Medication errors with serious consequences for the patient health often remain under-
reported [71]. Disclosing medication errors through the regular use of audit and failure
mode, effect, and criticality analysis (FMECA) improves the performance of individuals and
the reliability of healthcare systems [72]. Learning from near misses and errors improves
the culture of safety [66,73].
Medication practice should consider patients’ rights through the prescription of
medicines with the fewest side effects, and patient participation by informing them of
all possible adverse or undesirable effects. Patients’ health and well-being depend on
collaboration between patients and healthcare providers in a respectful alliance. Healthcare
providers serve patients as their advocates and respect their rights by providing them with
the decision-making capacity to be able to accept or refuse recommended medications [74].
Disguising medicines in food or drink is a common practice (43–71%) in the majority of
nursing homes [75] and is accompanied with incomplete documentation and consultation
with patients’ representatives or other healthcare providers, contravening the law [75,76].
The preservation of patients’ rights in the contemporary healthcare system is more compli-
cated than the linear process of medication administration and should consider the whole
process of medicines management [77,78]. Patients’ rights should encompass the discussion
of specific risks and benefits of proposed therapy with patients or their guardians and the
documentation of informed consent to medicine administration in the medical record [79].
Limitations of this review include the heterogeneity of the selected studies’ methods
and variations in their focus, which could impact the integration of the findings. A
thorough search process using multidimensional keywords applied commonly in the field
of healthcare was performed in international databases, but a few empirical studies were
retrieved, indicating a paucity of research on this important aspect of patient safety. Despite
the possibility of unintentional oversight by the authors in identifying all relevant keywords
for the search, the review provides a contemporary overview of the legal considerations
of medicines management as well as offering leads regarding aspects in need of further
elaboration in future studies.
5. Conclusions
The findings of this review identified significant individual and system factors re-
garding the legal considerations of medicines management in the healthcare system. A
summary of the review findings and suggested improvement strategies has been presented
in Table 4.
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Table 4. Improvement strategies based on the review findings.
Categories Areas of Interest Improvement Strategies
Healthcare providers’ education and
monitoring tasks
Insufficient knowledge and skills regarding medicines management,
particularly amongst unlicensed healthcare staff
Education and training regarding medicines preparation and
administration;
Direct supervision to ensure medicines management competencies
Lack of knowledge of and negative attitudes towards
pharmacovigilance legislation
Education on legislation influencing medicines management;
Improvement of culture surrounding patient safety;
Development of knowledge about the causes of medicines’ side effects
and ADRs
Effectiveness of legal monitoring guidelines to reduce medicines’
over-prescription and risky use
Application of standardised and contextually adapted checklists for safe
medication practice
Significance of validated tools for risk assessment and risk
management during the medication process
Use of monitoring tools by healthcare leaders to monitor healthcare staff
skills and healthcare environment to reduce errors and manage risks
Highlighting the role of electronic health record systems
Application of electronic health record systems for the communication
and documentation of the medication process;
Use of computerized medication decision support systems
Individual and shared responsibility
Difficulties in following rules and regulations
Improvement of working conditions;
Development of structured surveillance systems for prescribing,
administration, and monitoring
Importance of individual motivation to follow regulations Supporting ADR reporting and following up medicines managementguidelines
Significance of healthcare provider’s roles and mutual reasonability
towards safe medication practice
Education and training regarding the professional roles and duties of
healthcare staff;
Development of cultures of shared decision making;
Collaboration through communication and mutual feedback;
Clear task assignment and job description emphasising mutual
responsibility towards safe medicines management
Patients’ rights
Need for the detection, reporting of sentinel medication errors and
their appropriate compensation
Use of active error detection methods, analysis of and learning from
potential medication errors
Highlighting patients’ participation throughout the medication
process
Informing the patient about risks and benefits of medicines;
Inviting the patient to be involved in decision making regarding the
selection of medicine
ADRs: adverse drug reactions.
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These findings can be used for developing a framework of action to improve the safety
of medicines management and avoid legal issues affecting both the healthcare provider
and the patient.
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Appendix A
Table A1. The protocol for the systematic review of legal considerations surrounding medicines management in
healthcare settings.
Aspects and Definitions Practical Notes
Identification of the research
question




Legal considerations and strategies to ensure patient safety
through safe medicines management influencing on the
quality care in the healthcare system.
Review type An integrative systematicreview Both qualitative and quantitative studies will be considered.
Studies will be experimental, cross-sectional, qualitative, but
reviews, commentaries, letters, and books will be excluded.
Language English
Study designs All original research-basedstudies
Literature search
Researcher(s) An international team of researchers working on medicinesmanagement.
Databases
Electronic databases such as Scopus, PubMed [including
Medline], Cinahl, Web of Science for retrieving studies
published from 2010 to 2020.
Manual search and grey
literature
Important journals for manual search will be identified
during the references checking of retrieved articles selected
for full-text appraisal.
Grey literature includes policy documents, clinical
guidelines, and cross-references from bibliographies for
improving the search coverage.
Keywords
After a pilot search in databases, keywords for search to be
used via the Boolean Method are as follows:
(medication OR drug OR medicines OR “pharmaceutical
preparations” OR pharmaceuticals OR “medicines
management”) AND (law OR rule OR regulation OR
principle OR legislation OR Act OR guideline OR legal OR
bill OR convention OR policy OR obligation OR “breach of
duty” OR “legal duty” OR accountability OR responsibility
OR “patient’s right” OR litigation OR duty).
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Table A1. Cont.
Aspects and Definitions Practical Notes
Literature selection
Selecting original studies in
stages Based on titles, abstracts and full texts of articles.
Pre-tested inclusion criteria for
original studies
Explicit interest to the study topic; original and scientific
content related to the study topic; focused on the legal
considerations of medicines management in clinical practice
in short-term and long-term healthcare settings and
published in online peer-reviewed scientific journals.
Articles without an exact relevance on legal aspects and
considerations of medicines management in clinical practice
will be excluded.
Quality criteria




The whole process of review will be assessed using the
methodological checklist of systematic reviews and
meta-analyses developed by the http:
//prisma-statement.org/prismastatement/Checklist.aspx
PRISMA: Preferred Reporting Items Systematic Reviews and Meta-Analysis.
References
1. Nabhan, M.; Elraiyah, T.; Brown, D.R.; Dilling, J.A.; Leblanc, A.; Montori, V.M.; Morgenthaler, T.I.; Naessens, J.M.; Prokop, L.J.;
Roger, V.L.; et al. What is preventable harm in healthcare? A systematic review of definitions. BMC Health Serv. Res. 2012, 12, 128.
[CrossRef] [PubMed]
2. Runciman, W.B.; Merry, A.F.; Tito, F. Error, blame, and the law in health care—An antipodean perspective. Ann. Intern. Med. 2003,
138, 974–979. [CrossRef] [PubMed]
3. Guillod, O. Medical error disclosure and patient safety: Legal aspects. J. Public Health Res. 2013, 2, e31. [CrossRef] [PubMed]
4. World Health Organization (WHO). Conceptual Framework for the International Classification for Patient Safety Version 1.1. 2010.
Available online: https://www.who.int/patientsafety/implementation/taxonomy/ICPS-report/en/ (accessed on 15 June 2020).
5. World Health Organization (WHO). Patient Safety: Making Health Care Safer. 2017. Available online: https://apps.who.int/iris/
handle/10665/255507 (accessed on 15 June 2020).
6. Schwendimann, R.; Blatter, C.; Dhaini, S.R.; Simon, M.; Ausserhofer, D. The occurrence, types, consequences and preventability
of in-hospital adverse events—A scoping review. BMC Health Serv. Res. 2018, 18, 521. [CrossRef]
7. Light, D.W.; Lexchin, J.; Darrow, J.J. Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. J. Law
Med. Ethics 2013, 41, 590–600. [CrossRef]
8. World Health Organization (WHO). Patient Safety. 2020. Available online: https://www.who.int/patientsafety/en/ (accessed on
9 June 2020).
9. Donaldson, L.J.; Fletcher, M.G. The WHO World Alliance for Patient Safety: Towards the years of living less dangerously. Med. J.
Aust. 2006, 184, S69–S72. [CrossRef]
10. European Commission. Pharmaceutical Package. 2008. Available online: https://ec.europa.eu/health/human-use/package_en
(accessed on 8 June 2020).
11. European Commission. Patient Safety—Making It Happen! Luxembourg Declaration on Patient Safety. Luxembourg European
Commission, DG Health and Consumer Protection. 2005. Available online: https://ec.europa.eu/health/ph_overview/Documents/
ev_20050405_rd01_en.pdf (accessed on 9 June 2020).
12. International Council of Nurses (ICN). Patient Safety. 2020. Available online: https://www.icn.ch/nursing-policy/icn-strategic-
priorities/patient-safety (accessed on 17 February 2020).
13. Deslandes, P.; Pitcher, B.; Young, S. Medicines Management. Learning to Care: The Nursing Associate; Elsevier: Edinburgh, UK, 2019.
14. Organisation for Economic Cooperation and Development (OCED). Health at a Glance 2019-OECD Indicators. 2019. Available
online: https://doi.org/10.1787/4dd50c09-en (accessed on 15 June 2020).
15. World Health Organization (WHO). Human Rights and Health. 2017. Available online: https://www.who.int/news-room/fact-
sheets/detail/human-rights-and-health (accessed on 9 June 2020).
16. Council of Europe. Committee of Experts on Management of Safety and Quality in Health Care (SP-SQS) Expert Group
on Safe Medication Practices Glossary of Terms Related to Patient and Medication Safety. 2005. Available online: https:
//www.who.int/patientsafety/highlights/COE_patient_and_medication_safety_gl.pdf (accessed on 16 November 2020).
17. Food and Drug Administration (FDA). FDA Organization. 2020. Available online: https://www.fda.gov/about-fda/fda-
organization (accessed on 8 June 2020).
Medicina 2021, 57, 65 16 of 18
18. Patel, K.; Jay, R.; Shahzad, M.W.; Green, W.; Patel, R. A systematic review of approaches for calculating the cost of medication
errors. Eur. J. Hosp. Pharm. 2016, 23, 294–301. [CrossRef]
19. Jordan, S.; Logan, P.A.; Panes, G.; Vaismoradi, M.; Hughes, D. Adverse Drug Reactions, Power, Harm Reduction, Regulation and
the ADRe Profiles. Pharmacy 2018, 6, 102. [CrossRef]
20. Higgins, J.P.T.; Green, S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 2011. Available online:
http://handbook-5-1.cochrane.org/ (accessed on 21 May 2020).
21. Thomas, J.; Harden, A.; Oakley, A.; Oliver, S.; Sutcliffe, K.; Rees, R.; Brunton, G.; Kavanagh, J. Integrating qualitative research
with trials in systematic reviews. BMJ 2004, 328, 1010–1012. [CrossRef]
22. Strengthening the Reporting of Observational Studies (STROBE). 2009. Available online: https://www.strobe-statement.org/
index.php?id=available-checklists (accessed on 20 October 2020).
23. Critical Appraisal Skills Programme (CASP), Qualitative Checklist. 2018. Available online: https://casp-uk.net/wp-content/
uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf (accessed on 20 October 2020).
24. Mixed Methods Appraisal Tool (MMAT). 2018. Available online: http://mixedmethodsappraisaltoolpublic.pbworks.com/w/
page/24607821/FrontPage (accessed on 20 October 2020).
25. Moola, S.; Munn, Z.; Tufanaru, C.; Aromataris, E.; Sears, K.; Sfetc, R.; Currie, M.; Lisy, K.; Qureshi, R.; Mattis, P.; et al. Chapter 7:
Systematic Reviews of Etiology and Risk. JBI Man. Evid. Synth. 2020. [CrossRef]
26. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.A.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher,
D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
Explanation and elaboration. BMJ 2009, 339, b2700. [CrossRef]
27. Craftman, A.G.; Von Strauss, E.; Rudberg, S.L.; Westerbotn, M. District nurses’ perceptions of the concept of delegating
administration of medication to home care aides working in the municipality: A discrepancy between legal regulations and
practice. J. Clin. Nurs. 2013, 22, 569–578. [CrossRef]
28. Duarte, M.; Ferreira, P.; Soares, M.; Cavaco, A.M.; Martins, A.P. Community pharmacists’ attitudes towards adverse drug reaction
reporting and their knowledge of the new pharmacovigilance legislation in the southern region of Portugal: A mixed methods
study. Drugs Ther. Perspect. 2015, 31, 316–322. [CrossRef]
29. Karlsson, S.A.; Jacobsson, I.; Boman, M.D.; Hakkarainen, K.M.; Lövborg, H.; Hägg, S.; Jönsson, A.K. The impact of a changed
legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting. Eur. J. Clin. Pharmacol. 2015, 71,
631–636. [CrossRef] [PubMed]
30. Bolcato, M.; Fassina, G.; Rodriguez, D.; Russo, M.; Aprile, A. The contribution of legal medicine in clinical risk management.
BMC Health Serv. Res. 2019, 19, 1–6. [CrossRef] [PubMed]
31. Gøtzsche, P.C.; Vinther, S.; Sørensen, A. Forced medication in psychiatry: Patients’ rights and the law not respected by appeals
board in Denmark. Clin. Neuropsychiatry 2019, 16, 229–233. [CrossRef]
32. Strickler, G.K.; Zhang, K.; Halpin, J.F.; Bohnert, A.S.; Baldwin, G.T.; Kreiner, P.W. Effects of mandatory prescription drug
monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019,
199, 1–9. [CrossRef]
33. Stenner, K.; Edwards, J.; Mold, F.; Otter, S.; Courtenay, M.; Moore, A.; Carey, N. Medicines management activity with physiother-
apy and podiatry: A systematic mixed studies review. Health Policy 2018, 122, 1333–1339. [CrossRef]
34. Kapp, M.B. Teaching legal competencies through an individualized elective in medicine and law. Gerontol. Geriatr. Educ. 2018, 39,
491–494. [CrossRef] [PubMed]
35. Biddison, E.L.D.; Paine, L.; Murakami, P.; Herzke, C.; Weaver, S.J. Associations between safety culture and employee engagement
over time: A retrospective analysis. BMJ Qual. Saf. 2016, 25, 31–37. [CrossRef] [PubMed]
36. Pront, L.; Gillham, D.; Schuwirth, L.W.T. Competencies to enable learning-focused clinical supervision: A thematic analysis of the
literature. Med. Educ. 2016, 50, 485–495. [CrossRef] [PubMed]
37. Agoro, O.O.; Osuga, B.O.; Adoyo, M. Supportive supervision for medicines management in government health facilities in
Kiambu County, Kenya: A health workers’ perspective. Pan Afr. Med. J. 2015, 20, 237. [CrossRef] [PubMed]
38. Thomassen, Ø.; Storesund, A.; Søfteland, E.; Brattebø, G. The effects of safety checklists in medicine: A systematic review. Acta
Anaesthesiol. Scand. 2014, 58, 5–18. [CrossRef] [PubMed]
39. Vaismoradi, M.; Tella, S.; Logan, P.A.; Khakurel, J.; Vizcaya-Moreno, F. Nurses’ Adherence to Patient Safety Principles: A
Systematic Review. Int. J. Environ. Res. Public Health 2020, 17, 2028. [CrossRef] [PubMed]
40. Kane-Gill, S.L.; Dasta, J.F.; Buckley, M.S.; Devabhakthuni, S.; Liu, M.; Cohen, H.; George, E.L.; Pohlman, A.S.; Agarwal, S.;
Henneman, E.A.; et al. Clinical Practice Guideline: Safe Medication Use in the ICU. Crit. Care Med. 2017, 45, e877–e915. [CrossRef]
[PubMed]
41. Jordan, S.; Banner, T.; Gabe-Walters, M.; Mikhail, J.M.; Panes, G.; Round, J.; Snelgrove, S.; Storey, M.; Hughes, D. Nurse-led
medicines’ monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for
mental health medicines: An observational and interview study. PLoS ONE 2019, 14, e0220885. [CrossRef]
42. Halpern, K.J.; McKinnon, R.; Okolo, A.N.; Sanzio, T.M.; Dolan, C. A Medication Error and Legislation Designed to Punish: The
American Association of Nurse Attorneys Defends Just Culture in Nursing. J. Nurse Pract. 2016, 12, 109–112. [CrossRef]
43. Kellett, P.; Gottwald, M. Double-checking high-risk medications in acute settings: A safer process. Nurs. Manag. 2015, 21, 16–22.
[CrossRef]
Medicina 2021, 57, 65 17 of 18
44. Coleman, J.J.; Pontefract, S.K. Adverse drug reactions. Clin. Med. 2016, 16, 481–485. [CrossRef]
45. World Health Organization (WHO). Safety of Medicines: A Guide to Detecting and Reporting Adverse Drug Reactions-Why
Health Professionals Need to Take Action. 2002. Available online: http://archives.who.int/tbs/safety/esd_safety.pdf (accessed
on 12 June 2020).
46. Güner, M.D.; Ekmekci, P.E. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior
and factors determining the reporting rates. J. Drug Assess. 2019, 8, 13–20. [CrossRef]
47. Nadew, S.S.; Beyene, K.G.; Beza, S.W. Adverse drug reaction reporting practice and associated factors among medical doctors in
government hospitals in Addis Ababa, Ethiopia. PLoS ONE 2020, 15, e0227712. [CrossRef] [PubMed]
48. Thomas, R.E.; Nguyen, L.T.; Jackson, D.; Naugler, C. Potentially Inappropriate Prescribing and Potential Prescribing Omissions in
82,935 Older Hospitalised Adults: Association with Hospital Readmission and Mortality within Six Months. Geriatrics 2020, 5, 37.
[CrossRef]
49. Elnour, A.A.; Ahmed, A.D.; Yousif, M.A.E.; Shehab, A. Awareness and Reporting of Adverse Drug Reactions among Health Care
Professionals in Sudan. Jt. Comm. J. Qual. Patient Saf. 2009, 35, 324–329. [CrossRef]
50. Alemu, B.K.; Biru, T.T. Health Care Professionals’ Knowledge, Attitude, and Practice towards Adverse Drug Reaction Reporting
and Associated Factors at Selected Public Hospitals in Northeast Ethiopia: A Cross-Sectional Study. BioMed Res. Int. 2019, 2019,
8690546. [CrossRef]
51. Reumerman, M.O.; Tichelaar, J.; Piersma, B.; Richir, M.C.; Van Agtmael, M.A. Urgent need to modernize pharmacovigilance
education in healthcare curricula: Review of the literature. Eur. J. Clin. Pharmacol. 2018, 74, 1235–1248. [CrossRef] [PubMed]
52. Shchory, M.P.; Goldstein, L.H.; Arcavi, L.; Shihmanter, R.; Berkovitch, M.; Levy, A. The effect of an intervention program on the
knowledge and attitudes among medical staff regarding adverse drug reaction reporting. Pharmacoepidemiol. Drug Saf. 2020, 29,
1246–1253. [CrossRef]
53. Griffith, R.; Griffiths, H.; Jordan, S. Administration of medicines part 1: The law and nursing. Nurs. Stand. 2003, 18, 47–53.
[CrossRef]
54. The Nursing and Midwifery Council. Standards for Medicines Management. 2020. Available online: https://www.nmc.org.uk/
standards/standards-for-post-registration/standards-for-medicines-management/ (accessed on 9 June 2020).
55. Grissinger, M. The Five Rights: A Destination without a Map. Pharm. Ther. 2010, 35, 542.
56. Barnie, B.; Forson, P.K.; Opare-Addo, M.N.A.; Appiah-Poku, J.; Rhule, G.P.; Oduro, G.; Adu-Sarkodie, Y.; Donkor, P. Knowledge
and Perceptions of Health Workers’ Training on Ethics, Confidentiality and Medico-Legal Issues. J. Clin. Res. Bioeth. 2015, 6, 205.
[CrossRef]
57. Institute for Healthcare Improvement. Improvement Stories: The Five Rights of Medication Administration. 2020. Available
online: http://www.ihi.org/resources/Pages/ImprovementStories/FiveRightsofMedicationAdministration.aspx (accessed on 9
June 2020).
58. Tanga, H.Y. Nurse Drug Diversion and Nursing Leader’s Responsibilities. JONA’s Healthc. Law Ethics Regul. 2011, 13, 13–16.
[CrossRef]
59. O’Sullivan, D.; O’Mahony, D.; O’Connor, M.N.; Gallagher, P.; Cullinan, S.; O’Sullivan, R.; Gallagher, J.; Eustace, J.; Byrne, S. The
Impact of a Structured Pharmacist Intervention on the Appropriateness of Prescribing in Older Hospitalized Patients. Drugs
Aging 2014, 31, 471–481. [CrossRef] [PubMed]
60. Pearce, R.; Whyte, I. Editorial: Electronic medication management: Is it a silver bullet? Aust. Prescr. 2018, 41, 32–33. [CrossRef]
[PubMed]
61. Lee, L.M. Ethics and subsequent use of electronic health record data. J. Biomed. Inform. 2017, 71, 143–146. [CrossRef] [PubMed]
62. Van Biesen, W.; Decruyenaere, J.; Sideri, K.; Cockbain, J.; Sterckx, S. Remote digital monitoring of medication intake: Methodolog-
ical, medical, ethical and legal reflections. Acta Clin. Belg. 2019, 10, 1–8. [CrossRef] [PubMed]
63. Al Shemeili, S.; Klein, S.; Strath, A.; Fares, S.; Stewart, D. A modified Delphi study of structures and processes related to medicines
management for elderly hospitalised patients in the United Arab Emirates. J. Eval. Clin. Pract. 2016, 22, 781–791. [CrossRef]
[PubMed]
64. Mitty, E.; Resnick, B.; Allen, J.; Bakerjian, D.; Hertz, J.; Gardner, W.; Rapp, M.P.; Reinhard, S.; Young, H.; Mezey, M. Nursing
Delegation and Medication Administration in Assisted Living. Nurs. Adm. Q. 2010, 34, 162–171. [CrossRef]
65. O’Sullivan, M.-J.; Rae, S. Shared decision-making in psychiatric medicines management. Ment. Health Pract. 2014, 17, 16–22.
[CrossRef]
66. Kavanagh, C. Medication governance: Preventing errors and promoting patient safety. Br. J. Nurs. 2017, 26, 159–165. [CrossRef]
67. Vaismoradi, M.; Vizcaya-Moreno, F.; Jordan, S.; Kymre, I.G.; Kangasniemi, M. Disclosing and Reporting Practice Errors by Nurses
in Residential Long-Term Care Settings: A Systematic Review. Sustainability 2020, 12, 2630. [CrossRef]
68. Aag, T.; Garcia, B.H.; Viktil, K.K. Should nurses or clinical pharmacists perform medication reconciliation? A randomized
controlled trial. Eur. J. Clin. Pharmacol. 2014, 70, 1325–1332. [CrossRef]
69. Mardani, A.; Griffiths, P.; Vaismoradi, M. The Role of the Nurse in the Management of Medicines during Transitional Care: A
Systematic Review. J. Multidiscip. Healthc. 2020, 13, 1347–1361. [CrossRef] [PubMed]
70. Afolalu, O.O.; Jordan, S.; Kyriacos, U. Medical error reporting among doctors and nurses in a Nigerian hospital: A cross sectional
survey. J. Nurs. Manag. 2020. [CrossRef] [PubMed]
Medicina 2021, 57, 65 18 of 18
71. Ferrah, N.; Lovell, J.J.; Ibrahim, J.E. Systematic Review of the Prevalence of Medication Errors Resulting in Hospitalization and
Death of Nursing Home Residents. J. Am. Geriatr. Soc. 2017, 65, 433–442. [CrossRef] [PubMed]
72. Montesi, G.; Lechi, A. Prevention of medication errors: Detection and audit. Br. J. Clin. Pharmacol. 2009, 67, 651–655. [CrossRef]
73. Lawton, R.; Carruthers, S.; Gardner, P.; Wright, J.; McEachan, R. Identifying the Latent Failures Underpinning Medication
Administration Errors: An Exploratory Study. Health Serv. Res. 2012, 47, 1437–1459. [CrossRef]
74. American Medical Association. Patient Rights: Code of Medical Ethics Opinion 1.1.3. 2020. Available online: https://www.ama-
assn.org/delivering-care/ethics/patient-rights (accessed on 9 June 2020).
75. Haw, C.M.; Stubbs, J. Covert administration of medication to older adults: A review of the literature and published studies. J.
Psychiatr. Ment. Health Nurs. 2010, 17, 761–768. [CrossRef] [PubMed]
76. Munden, L.M. The Covert Administration of Medications: Legal and Ethical Complexities for Health Care Professionals. J. Law
Med. Ethics 2017, 45, 182–192. [CrossRef]
77. Blignaut, A.J.; Coetzee, S.K.; Klopper, H.C.; Ellis, S.M. Medication administration errors and related deviations from safe practice:
An observational study. J. Clin. Nurs. 2017, 26, 3610–3623. [CrossRef]
78. Martyn, J.-A.; Paliadelis, P.S.; Perry, C. The safe administration of medication: Nursing behaviours beyond the five-rights. Nurse
Educ. Pract. 2019, 37, 109–114. [CrossRef]
79. Rose, R.V.; Kass, J.S. Prescribing Antipsychotic Medications to Patients with Dementia. Contin. Lifelong Learn. Neurol. 2019, 25,
254–259. [CrossRef]
